
iBio (IBIO) Stock Forecast & Price Target
iBio (IBIO) Analyst Ratings
Bulls say
iBio is attractive because its lead asset IBIO-610 is backed by unusually strong, internally consistent preclinical data across rodents and NHPs, with up to 98% Activin E inhibition, improved body composition, and evidence that it can preserve lean mass while enhancing semaglutide-driven fat loss and limiting rebound after withdrawal. The thesis is further strengthened by human genetics and emerging competitor human data validating Activin E biology in visceral fat, liver fat, and diabetes protection, while the broader platform adds optionality through IBIO-800, IBIO-600, and the amylin program, each aimed at differentiated, ligand-selective mechanisms in large or less-crowded markets. Financially, the company had about $88.0 million in cash, cash equivalents, and investments in debt securities as of June 30, 2026, with runway extending into 2028, which supports execution through upcoming catalysts including an IND/CTA by year-end 2026 and first-in-human studies in 1H27.
Bears say
iBio is a clinical-stage company with no products generating revenue, persistent operating losses since inception, and a likely need for additional debt or equity funding to support research, regulatory work, and future commercialization, creating meaningful dilution risk. Its pipeline also faces significant clinical uncertainty: activin-pathway safety concerns have been highlighted by pericardial effusions, cardiopulmonary hospitalizations, and other serious adverse events in comparable programs, while iBio’s own candidates still face unresolved questions on dose selection, biomarker strategy, and the ability to compete on endpoints such as MRI-PDFF. On top of that, manufacturing reliance on third parties, competitive pressure from better-capitalized peers, and regulatory, IP, and litigation risks all weaken confidence in long-term value creation.
This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.
iBio (IBIO) Analyst Forecast & Price Prediction
Start investing in iBio (IBIO)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About iBio (IBIO) Forecast
iBio (IBIO) Analyst Forecast & Price Prediction
Start investing in iBio (IBIO)
Order type
Buy in
Order amount
Est. shares
0 shares